

Weekly healthcare technology, medtech and life-science investment intelligence

GE HealthCare to Acquire SOFIE Biosciences for \$945M, Expanding U.S. Radiopharmaceutical Footprint

GE HealthCare agreed to acquire SOFIE Biosciences in cash, adding 15 U.S. radiopharmaceutical manufacturing sites, 21 cyclotrons and a theranostics-focused CDMO operation. The transaction also gives GE HealthCare U.S. rights to FAPI-74, a Phase III PET radiotracer with pan-cancer imaging potential, strengthening its position across imaging, diagnostics and the fast-growing radiopharma supply chain. [Link](#)

EliseAI Raises \$350M at a \$4B Valuation to Expand AI Automation Across Healthcare and Housing

Andreessen Horowitz and Bessemer Venture Partners led the financing, with Ontario Teachers' Pension Plan, Sapphire Ventures and Navitas Capital participating. EliseAI automates administrative and patient-facing workflows for specialty healthcare organizations, and the new capital will support deeper workflow automation and expansion of its engineering, deployment and sales teams. [Link](#)

TriGemX Bio Raises \$94M and Launches Phase III Program for Oral Migraine Therapy

Formerly Kallyope, TriGemX raised \$94 million co-led by The Column Group, TCGX and Viking Global Investors. The financing supports pivotal development of elismetrep, an oral TRPM8 channel blocker for acute migraine, and reflects investor willingness to fund differentiated, genetics-linked neurology programs through late-stage clinical testing. [Link](#)

R1 Therapeutics Expands Series A to \$80.5M Ahead of Phase IIb Kidney-Disease Readout

Samsara BioCapital joined Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital and U.S. Renal Care. R1 is advancing AP306, a first-in-class pan-phosphate transporter inhibitor for hyperphosphatemia in dialysis patients, with Phase IIb topline data expected in the first half of 2027. [Link](#)

Breye Therapeutics Raises €67.5M Series A for Oral Treatment of Diabetic Retinopathy

Mission BioCapital and Novo Holdings co-led the oversubscribed round with Sound Bioventures and additional investors. Breye will move danegaptide into a randomized Phase II study in non-proliferative diabetic retinopathy and advance additional retinal-disease programs, highlighting continued investor interest in therapies that can reduce the burden of chronic injectable eye treatments. [Link](#)

ai3Bio Launches With \$48M Series A to Target Disease-Causing T Cells in Autoimmune Disorders

UPMC Enterprises and Ziff Capital Partners led the financing, with Cockrell Interests and Tanis Ventures participating. The company combines an LNP/mRNA platform and an antibody platform designed to selectively eliminate pathogenic Th17 cells, aiming to address autoimmune disease at its source rather than only suppress symptoms. [Link](#)

Aptadir Therapeutics Raises €40M Seed Round for RNA-Based Demethylating Medicines

4BIO Capital led the financing with participation from EXTEND and additional investors. Aptadir is developing DNMT1-interacting RNA therapeutics designed to reverse abnormal gene silencing, with its lead Fragile X syndrome program representing a new approach to treating diseases driven by pathological DNA methylation. [Link](#)

Tiny Health Raises \$33M Series B to Expand Microbiome Intelligence Platform

B Capital led the financing, bringing total funding to approximately \$46 million. Tiny Health has expanded from infant gut testing into gut and vaginal microbiome intelligence across the lifespan, serving nearly 200,000 customers and more than 6,000 practitioners while developing research programs in inflammatory bowel disease, menopause and oncology response. [Link](#)

Parakeet Health Raises \$10M Series A After 10x Growth in AI-Powered Patient Access

Canvas Ventures led the oversubscribed round with Blank Space Ventures, StoryHouse Ventures and HMC INQ. Parakeet automates patient access workflows including scheduling, referral management and outreach, and says it now serves six of the 10 largest U.S. dermatology groups—evidence that AI patient-access platforms are moving from pilots into scaled specialty-practice deployment. [Link](#)

Biotia Raises \$9M to Scale Genomic Diagnostics for Complex Infections

The oversubscribed financing will expand Biotia's laboratory capacity and launch additional diagnostics in women's health and orthopedics. Its BIOTIA-ID urine test uses clinical metagenomics to identify organisms in recurrent and complicated urinary tract infections, illustrating continued investment in diagnostics that move beyond conventional culture-based testing. [Link](#)

Aleph Surgical Raises \$7.5M Pre-Seed Led by Andreessen Horowitz for Autonomous Surgical Robotics

BoxGroup, Reveille VC, Constellation, FDVC, Valkyrie Ventures, Discipulus Ventures and Maniac Ventures also participated. Aleph is building a robotic surgical system designed to learn procedures from demonstrations and improve through experience, making it one of the clearest early-stage bets on physical AI entering high-value clinical labor. [Link](#)

Becker's: Google Says Gemini 4 Argon Found a Critical Vulnerability in Hospital Software

Becker's reports that Google's new frontier model identified and validated a critical vulnerability in healthcare software used by hospitals worldwide through Wiz's Scan for Good initiative. Google has not named the affected product, but the announcement is significant for health systems because it shows frontier AI moving from productivity tools into autonomous cybersecurity discovery and patching. [Link](#)

Upcoming Events

October 14, 2026 — Rock Health Summit — San Francisco, CA

Rock Health's annual digital-health gathering brings together founders, investors, health-system executives, payers and enterprise leaders. The 2026 agenda includes policy, product and investment in the age of AI, making it directly relevant to HDIG's innovation and capital-markets work. [Link](#)

October 18–21, 2026 — The MedTech Conference, Hosted by AdvaMed — Boston, MA

AdvaMed expects 4,000+ leaders from 1,800+ companies and 40+ countries, with programming across AI, digital health, diagnostics, imaging, M&A, regulatory strategy and partnering—one of the strongest near-term venues for medtech commercialization and investor relationships. [Link](#)

October 27–28, 2026 — BioFuture 2026 — New York, NY

BioFuture connects therapeutic innovators, digital-health companies, policymakers and investors through company presentations, partnering and discussions on biopharma, AI, TechBio, big data and regulatory change. [Link](#)